FDA Approves QIAGEN N.V. KRAS Test for Use With Eli Lilly and Company and Bristol-Myers Squibb Company's Cancer Drug Erbitux
Published: Jul 09, 2012
QIAGEN NV has received US FDA approval to market the therascreen KRAS RGQ PCR Kit (therascreen KRAS test) to provide guidance on the use of Erbitux (cetuximab) as a treatment in patients with metastatic colorectal cancer. The US FDA approval of the KRAS test kit marks a milestone in QIAGEN's global expansion of its Personalized Healthcare franchise which includes an industry-leading portfolio of molecular companion diagnostics to aid treatment decisions in oncology. QIAGEN already markets a broad range of companion diagnostic tests covering 30 biomarkers in Europe, Asia/Pacific and Japan.